Nowadays, two anti-PD-1 inhibitors, pembrolizumab (PEMBRO) [17], cemiplimab (CEMI) [18], and one anti-PD-L1 inhibitor, atezolizumab (AT) [19], have been approved as monotherapy in first-line treatment of adult NSCLC patients with high PD-L1 expression (in ≥50% tumor cells) with no EGFR, ALK, or ROS1 aberrations. This evidence concerns the gene CD274 and neoplasm.